论文部分内容阅读
本文目的是验证温州制药厂研制的法莫替丁治疗消化性溃疡病的效果及其安全性。由北京和浙江五所医院,用双盲双模拟的研究方法,共观察151例消化性溃疡病病人,其研究结果为法莫替丁40mg/d(对照西米替丁800mg/d),胃溃疡治疗6周,其溃疡愈合率和总有效率为77.3和90.9%(对照75.0和83.3%);十二指肠溃疡治疗4周,其溃疡愈合率和总有效率为74.7和90.7%(对照66.7%和73.8%),十二指肠溃疡的总有效率,法莫替丁组高于西米替丁组(p<0.05)。对疼痛的缓解,两组间无差异性(p>0.05)。治疗期间未发现明显副作用。
The purpose of this paper is to verify the efficacy and safety of famotidine developed by Wenzhou Pharmaceutical Factory in the treatment of peptic ulcer disease. A total of 151 patients with peptic ulcer disease were observed by double-blind double-dummy study in five hospitals in Beijing and Zhejiang Province. The results of the study were famotidine 40 mg / d (control cimetidine 800 mg / d), gastric ulcer After 6 weeks treatment, ulcer healing rate and total effective rate were 77.3% and 90.9% (control 75.0% and 83.3% respectively). Duodenal ulcer treatment for 4 weeks showed ulcer healing rate and total effective rate 74.7 and 90.7% (control 66.7 % And 73.8%, respectively. The total effective rate of duodenal ulcer was higher in famotidine group than in cimetidine group (p <0.05). Pain relief, no difference between the two groups (p> 0.05). No significant side effects were found during treatment.